|By PR Newswire||
|April 8, 2014 01:07 AM EDT||
LONDON, April 8, 2014 /PRNewswire/ -- The arrival of new oral drugs for treatment of hepatitis C will dramatically shift the landscape of therapy from being physician-driven to patient-led, raising questions about best practices for adherence. A White Paper published by Atlantis Healthcare offers a roadmap of the new therapeutic environment for pharma industry, healthcare providers and payors, including clinical insights, non-adherence predictors and proven interventions to improve adherence.
"Adherence is critical and we need to be on top of that," said Professor David Goldberg, leader of Health Protection Scotland's hepatitis C programme and contributor to the latest report from the Adherence Research Summarized™ series. "The new drugs are expensive and there is the possibility that the virus could become resistant if adherence is sub-optimal, so we will need to support people to take the medication."
Hepatitis C is a virus carried in the blood affecting 170 million people worldwide. It is estimated that nearly 215,000 people in the UK have chronic hepatitis C and there are approximately 10,000 new cases diagnosed each year1. According to the report, while therapy offers the possibility of cure, the majority of people living with hepatitis C do not receive treatment. For those who do start treatment, good outcomes are dependent on a high level of adherence.
Current treatment for hepatitis C involves weekly interferon injections combined with oral drugs. Side effects, include fatigue, headache and depression, are the most common reason for discontinuing treatment. The new drugs are in simple pill form, bypassing the need for injections or frequent hospital visits, and offer shorter duration of treatment and improved effectiveness.
"With the new therapies coming on line, much of the demand for the treatment will come from the patients, " said Dr. Goldberg. "They will hear it's much easier to take, more effective, has fewer side effects and can be taken without disrupting one's work."
However, Dr. Christina Jackson, senior health psychology specialist from Atlantis Healthcare, cautions there are still a number of other barriers to adherence a patient faces. "Research shows that across a number of disease states, levels of non-adherence can be high even where the treatment regimen is simple2".
According to the report, the greater patient responsibility in hepatitis C therapy will present challenges to the healthcare community, especially when supporting hepatitis C patients who have other chronic conditions. Research reviewed indicates that simple patient-led interventions, including personalized nursing support and supplemental patient education from a health care provider other than the physician, can help increase treatment adherence.
For more information and to download the report, visit http://atlantishealthcare.com/hepatitis-c-white-paper/
 Saini et al. (2009)
Sep. 1, 2015 08:15 PM EDT Reads: 408
Sep. 1, 2015 07:00 PM EDT Reads: 269
Sep. 1, 2015 06:45 PM EDT Reads: 475
Sep. 1, 2015 04:30 PM EDT Reads: 387
Sep. 1, 2015 04:15 PM EDT Reads: 433
Sep. 1, 2015 04:00 PM EDT Reads: 196
Sep. 1, 2015 04:00 PM EDT Reads: 207
Sep. 1, 2015 03:00 PM EDT Reads: 509
Sep. 1, 2015 03:00 PM EDT Reads: 439
Sep. 1, 2015 02:45 PM EDT
Sep. 1, 2015 02:45 PM EDT Reads: 137
Sep. 1, 2015 02:30 PM EDT Reads: 214
Sep. 1, 2015 01:00 PM EDT
Sep. 1, 2015 12:45 PM EDT Reads: 478
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Sep. 1, 2015 12:30 PM EDT Reads: 912